126 results on '"Koehm, Michaela"'
Search Results
2. The Potential of Digital Twins in Healthcare: Evaluation of a Clinical Decision Support System for Chronic Inflammatory Bowel Disease
3. Short-term predictor for COVID-19 severity from a longitudinal multi-omics study for practical application in intensive care units
4. Aligning Subjective Ratings in Clinical Decision Making
5. Automated Hand Joint Classification of Psoriatic Arthritis Patients Using Routinely Acquired Near Infrared Fluorescence Optical Imaging
6. Machine Learning Based Approach for Motion Detection and Estimation in Routinely Acquired Low Resolution Near Infrared Fluorescence Optical Imaging
7. An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo–controlled, single-center, phase 1/2 proof-of-concept study
8. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research
9. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial
10. How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients.
11. An international multicentre analysis of current prescribing practices and shared decision-making in psoriatic arthritis.
12. Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study
13. Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies
14. How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients
15. An international multi-centre analysis of current prescribing practices and shared decision-making in psoriatic arthritis
16. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities
17. Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study
18. Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab
19. Psoriatic Arthritis
20. ‘Status Quo’ on Different Aspects of Gender Distribution in Rheumatology in Germany—Results from a Nationwide Online Survey among Physicians
21. Dual-Energy CT in Patients with Suspected Gouty Arthritis:: Effects on Treatment Regimen and Clinical Outcome
22. Synthetic DMARDs
23. Use of a “critical difference” statistical criterion improves the predictive utility of the Health Assessment Questionnaire-Disability Index score in patients with rheumatoid arthritis
24. Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial.
25. P178 Current prescribing practices in psoriatic arthritis - comparison between the UK and Europe
26. P179 Shared decision-making in psoriatic arthritis consultations
27. Correction to: Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study
28. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial
29. Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis
30. Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)
31. Fluorescence-optical imaging as a promising easy-to-use imaging biomarker to increase early psoriatic arthritis detection in patients with psoriasis: a cross-sectional cohort study with follow-up
32. An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo-controlled, single-center, phase 1/2 proof-of-concept study
33. Management of Enthesitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
34. Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis
35. Management of Enthesitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
36. Genetic Analysis of MPO Variants in Four Psoriasis Subtypes in Patients from Germany
37. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis
38. Rare Loss-of-Function Mutation in SERPINA3 in Generalized Pustular Psoriasis
39. Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
40. Towards an Ontology Representing Characteristics of Inflammatory Bowel Disease
41. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: A longitudinal EUSTAR study
42. Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab
43. Rheumatoid arthritis - treatment: 180. Utility of Body Weight Classified Low-Dose Leflunomide in Japanese Rheumatoid Arthritis
44. Effectiveness of Different Dosages of Retreatment of Rituximab in Combination with Leflunomide: Results from a Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study
45. Association of Improvement in Pain With Therapeutic Response as Determined by Individual Improvement Criteria in Patients With Rheumatoid Arthritis
46. Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis
47. Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study
48. Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study.
49. Update 2011: leflunomide in rheumatoid arthritis – strengths and weaknesses
50. Rheumatoid arthritis - treatment: 180. Utility of Body Weight Classified Low-Dose Leflunomide in Japanese Rheumatoid Arthritis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.